Treatment

Lecanemab: drawbacks to consider

Lecanemab: a review

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Lecanemab vs aducanumab

Targeting the pancreas to treat Alzheimer’s disease

Diabetes-associated cognitive dysfunction

New pivotal study using photobiomodulation in Alzheimer’s treatment

The regulatory role of nicotinic receptors in cognitive functioning

The importance of using systems biology based approaches in AD research

How effective are cholinergic agents beyond MCI?

Highlights from CTAD 2022

Prioritizing the mechanistic understanding of AD to improve treatments

Photobiomodulation: why target the brain and the gut?

APOE-targeted epigenome therapy for Alzheimer’s disease

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD